Comparability Between Recombinant Factor C and Traditional LAL Assay in Endotoxin Detection

Try Our Recombinant Factor C Endotoxin Detection Kit (RES-A056) for Free!

Click to Apply Now!

Background

Endotoxin detection is a critical component of quality control in biopharmaceutical production. Traditionally, the Limulus Amebocyte Lysate (LAL) assay has been the gold standard. However, the LAL method relies heavily on horseshoe crab blood, raising concerns about supply chain stability, animal welfare, and false positives due to β-glucan interference with Factor G pathways.

As a sustainable, animal-free alternative, the Recombinant Factor C (rFC) method utilizes genetically engineered Factor C proteins to specifically recognize lipopolysaccharide (LPS), the active component of endotoxins. Without activation of secondary pathways, rFC ensures greater specificity and is increasingly supported by global pharmacopeias and regulatory bodies.

Performance and Comparability Studies

(1) Sensitivity and Consistency

Multiple studies have demonstrated that rFC is highly comparable to LAL in sensitivity. For instance:

• In samples such as non-potable water, clean steam, and water for injection (WFI), both methods achieved 50–200% recovery rates.

• rFC and LAL showed identical non-detection rates for WFI and clean steam samples.

• In testing 41 waterborne bacterial contamination samples, rFC and LAL results over 85% consistency, around to the 95% variation observed between LAL assay.

(2) Resistance to Interference

rFC operates solely via the Factor C pathway, avoiding interference from β-glucans and other non-endotoxin substances. This minimizes false positives and makes it better suited for complex sample matrices.

In vaccine production, intermediate products often contain high levels of recombinant proteins or detergents that inhibit LAL performance. rFC, with optimized pre-treatment (e.g., dilution), can accurately quantify endotoxins in these challenging samples.

(3) Quantification and Trend Analysis

rFC demonstrates a high correlation with LAL (R² > 0.98) when using kinetic chromogenic methods, supporting process monitoring and trend analysis.

Moreover, rFC maintains reliable detection of endotoxins from bacteria grown in low-nutrient environments like M9 medium, where LAL may require greater dilution due to complex sample backgrounds.

Comparison of LAL Assay and Recombinant Factor C Assay Detection Procedures

Regulatory Landscape and Method Validation

(1) Global Pharmacopeial Adoption

• European Pharmacopoeia (Ph. Eur.): Officially incorporated rFC as an independent method in Chapter 2.6.32 (2021).

• United States Pharmacopeia (USP): Chapter<86>(2023) recognizes rFC as an alternative, requiring method validation (e.g., interference tests, linearity).

(2) Key Validation Requirements

• Interference Testing: Validate recoveries within 50–200% at the maximum valid dilution (MVD). If interference (e.g., low endotoxin recovery) occurs, optimize sample prep via ultrafiltration or chelating agents.

• Comparability Protocols: According to USP<1225>, switching methods or suppliers require comparability data. The FDA classifies such changes under CBE-0 or CBE-30 submission pathways.

Advantages of rFC in Endotoxin Detection

• Stable Supply Chain: Biotechnologically produced rFC avoids reliance on horseshoe crabs and aligns with the 3Rs principle (Replacement, Reduction, Refinement).

• High Specificity: Eliminates interference from β-glucans, fungal polysaccharides, or plant-derived components—ideal for samples filtered through cellulose or containing botanical extracts.

• Regulatory Momentum: Already accepted by the Ph. Eur. and encouraged by the FDA in early clinical phases to mitigate risk.

Looking Ahead

Recombinant Factor C (rFC) offers superior sensitivity, specificity, and sustainability compared to traditional LAL reagents, making it especially suitable for complex samples and global manufacturing environments. With USP<86>now in effect, a new era of harmonized global standards for endotoxin testing is underway. Looking ahead, rFC is well-positioned to gradually replace LAL as the mainstream method—delivering a more robust solution for endotoxin control in complex biologics such as cell therapies.

Recombinant Factor C Endotoxin Detection Solution

ACROBiosystems has developed a recombinant Factor C endotoxin detection kit (Cat. No. RES-A056) based on endpoint fluorescence detection. Tailored for pharmaceuticals, medical devices, and biologic products, this kit supports rigorous QC standards across the industry.

Core Advantages

• Fully validated Recombinant Factor C method (Ph. Eur. 11.0 and USP<1225> guidelines).USP<86> has officially recognized the Recombinant Factor C (rFC) assay for endotoxin detection.

• High concordance with traditional LAL methods, third-party validation available.

• Superior specificity: Effectively eliminates β-glucan interference.

• High accuracy: Endotoxin standards traceable to USP Standard (Cat. No: 1235503).

• Rapid results: Assay completion in under an hour.

• Industry-leading sensitivity: Detects endotoxin from 0.005 - 5 EU/mL.

Learn More

Validation Data

High sensitivity, detection results comparable to LAL method

Different methods were used to detect endotoxin residues in five samples, and the deviation between the detection results of rFC method and LAL method is within 2 times.

Free Resources Here

Recommended Products

• Mycoplasma Rapid Detection Kit

• Host DNA Residue Detection Kits

• T7 RNA Polymerase Residue Detection Kit

• DNase Activity Assay Kit (Fluorescence)

• resDetect™ Process Residue Detection Solutions

Upcoming Endotoxin Detection Insights Series:

Part 1: Strategies for Mitigating β-Glucan Interference in Endotoxin Detection

Part 2: Application of Recombinant Factor C Endotoxin Testing in Pharmaceutical Manufacturing

Part 3: Standards and Regulations for Recombinant Factor C Endotoxin Testing from a Pharmacopoeial Perspective

Part 4: Comparison of Recombinant Factor C and Other LAL Methods

Part 5: A Comprehensive Guide to Sample Dilution Calculations for Recombinant Factor C Endotoxin Testing

Part 6: Key Considerations for Endotoxin Testing Experimental Procedures

Part 7: Interfering Factors in Endotoxin Testing